Company Description
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity.
The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in Phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow.
It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis (MASH); and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity, as well as TERN-800 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity.
The company was incorporated in 2016 and is headquartered in Foster City, California.
| Country | United States |
| Founded | 2017 |
| IPO Date | Feb 5, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 59 |
| CEO | Amy Burroughs |
Contact Details
Address: 1065 East Hillsdale Boulevard, Suite 100 Foster City, California 94404 United States | |
| Phone | 650 525 5535 |
| Website | ternspharma.com |
Stock Details
| Ticker Symbol | TERN |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $17.00 |
| CIK Code | 1831363 |
| CUSIP Number | 880881107 |
| ISIN Number | US8808811074 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Amy L. Burroughs M.B.A. | Chief Executive Officer and Director |
| Melita Sun Jung | Chief Business Officer |
| Andrew W. Gengos | Chief Financial Officer and Head of Corporate Development |
| Scott Harris | Chief Development and Operations Officer |
| Caryn Gordon McDowell J.D. | Chief Legal Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 17, 2026 | SCHEDULE 13G/A | Filing |
| Feb 13, 2026 | SCHEDULE 13G/A | Filing |
| Feb 13, 2026 | SCHEDULE 13G/A | Filing |
| Feb 12, 2026 | SCHEDULE 13G/A | Filing |
| Feb 12, 2026 | SCHEDULE 13G | Filing |
| Jan 22, 2026 | 8-K | Current Report |
| Jan 15, 2026 | 144 | Filing |
| Jan 9, 2026 | 8-K | Current Report |
| Dec 11, 2025 | 8-K | Current Report |
| Dec 11, 2025 | 424B5 | Filing |